Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-kappa monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al[1][2].
Molecular Weight:
(143.69 kDa)
Purity:
98.80
CAS Number:
[1798286-48-2]
Target:
PD-1/PD-L1
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
